JAMA reports that in moderate to severe ARDS, inhaled sevoflurane sedation led to fewer ventilator-free days and lower 90-day survival than intravenous propofol, with safety concerns including acute kidney injury.
In adults with moderate to severe #ARDS, inhaled sevoflurane sedation produced fewer ventilator-free days and lower 90-day survival than intravenous propofol, raising safety concerns including acute kidney injury.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare